Biotechnologie Spitzen-Cluster München und Osaka (Japan) vereinbaren enge Kooperation

Austausch insbesondere im Technologietransfer

(PresseBox) (Martinsried, ) Feierliche Unterzeichnung der Kooperationsvereinbarung zwischen den Biotechnologie Clustern

Osaka, München, 4. Oktober 2011. Die Repräsentanten der Biotech Cluster Organisationen von München, Deutschland, und Osaka, Japan, haben heute eine transnationale Biotech und Life Science Kooperationsvereinbarung unterzeichnet, die eine enge Zusammenarbeit der Regionen vorsieht.

Die Partnerschaft beeinhalten den Austauch von Informationen über die neuesten Technologien in der jeweiligen Region, industrielle Entwicklungen und das akademische Potential, sowie den Austausch von best practices im Technologietransfer und der Unterstützung von Biotech KMU. Dies soll den Weg ebnen für Industrie-Industrie- und Industrie-Akadmie-Kooperationen zwischen den beiden Regionen.

Dr. Tadamitsu Kishimoto, Präsident der Osaka Bio Headquarters (Senri Life Sciences Foundation) sagte:”Da sowohl Osaka als auch München führende Biotech Standorte in ihren Ländern sind, bedeutet die Vereinbarung einen Gewinn für beide Partner. Die Beteiligung von Forschungsinsitituten und Technologietransfer Organisationen und der regelmäßige Informationsaustausch wird dazu beitragen, die best practices schnell umzusetzten.“

“Um in dieser komplexen Branche erfolgreich zu sein, sind persönliche Kontakte entscheidend”, sagte Prof. Dr. Horst Domdey, Geschäftsführer der BioM Biotech Cluster Development GmbH, München. „Auf Grundlage der Kooperationsvereinbarung, werden wir regelmäßig Geschäftsreisen und Partnerings organisieren, um ein kontinuierliches persönliches Gespräch zu ermöglichen. Damit wird der Zugang zu interessanten Märkten und Forschungskooperationen erleichtert.“

Die feierliche Unterzeichnung fand am heutigen 4. Oktober um 10 Uhr im Osaka Prefectural Meeting House statt. Das Programm bestand aus Festreden der unterzeichnenden Partnern und Vertretern der Regierung der Präfektur Osaka, dem Deutschen Generalkonsul in Osaka-Kobe und dem japanischen Büro des Freistaats Bayern.


Weitere Informationen:
BioM Biotech Cluster Development GmbH
www.bio-m.org
Dr. Georg Kääb
Email: kaeaeb@bio-m.org

Contact Details:
BioM Biotech Cluster Development GmbH
Am Klopferspitz 19a
82152 Martinsried
Germany
phone: +49-89-89 96 79-0
fax: +49-89-89 96 79-79

www.bio-m.org

Englischsprachige Meldung:

Leading Biotechnology Clusters of Osaka and Munich join forces
Ceremonial signing of Memorandum of Understanding

Osaka, Oct 4th, 2011. The representatives of the Biotech Cluster Organizations of Munich, Germany and Osaka, Japan, today signed a Transnational Biotech & Life Science Cooperation Partnership Agreement declaring a close cooperation in the future.
The cooperation schemes include an exchange of information about each region’s new technologies, industry developments and academic potential and an exchange of best practices in technology transfer and biotech SME support. This will pave the way to the initiation of industry-industry and industry-academy partnerships between the two regions.
Dr. Tadamitsu Kishimoto, President of Osaka Bio Headquarters (Senri Life Sciences Foundation) stated:”Since both Osaka and Munich are leading biotech locations in their countries, the agreement is of mutual benefit for our organizations. The involvement of research institutions and tech-transfer organizations and the regular information exchanges will help to bring best practices quickly into practice.”
“For being successful in this complex business, you need to have personal contacts”, stated Prof. Dr. Horst Domdey, CEO of BioM Biotech Cluster Development GmbH, Munich. “Following the agreement, we will organize trade missions on a regular basis in order to enable regular face to face matchmakings. This will help to get access to interesting new markets and research collaborations.”
The signing ceremony took place in the Osaka Prefectural Meeting House on October 4th, 2011 at 10:00 a.m. The program included speeches of the signing parties and the witnesses, namely Osaka Prefectural Government, Osaka University, as well as the German Consulate General in Osaka – Kobe and the State of Bavaria – Japan Office.

About the Osaka Biotechnology Region
Kansai is one of the leading life science hubs in Japan. The region includes Osaka and the neighboring Kobe regions and has a large concentration of renowned universities and research institutes with outstanding research and development capabilities. For industry, the high representation of pharmaceutical companies is especially interesting. The Northern Osaka Biomedical Cluster covers a 20 km radius and includes Saito Life Science Park that is located on the green hills in northern Osaka, the Dosho-machi district known as the “pharmaceutical town” housing over 300 pharmaceutical and other bio-related companies, a membership organization “Protein Mall Kansai”, which constitutes of more than 80 protein related companies and supporting bodies, and a number of research institutes located in Suita and Toyonaka cities.

In Saito Life Science Park, three incubation facilities are maintained, which house 40 pharmaceutical and biotech start-up companies along with world-leading National Institute of Biomedical Innovation (NIBIO).
In the surrounding area of Saito Life Science Park, the Institute of Protein Research and the National Cerebral and Cardiovascular Center (NCVC), the Osaka Bioscience Institute (OBI), the National Institute of Advanced Industrial Science and Technology (AIST) Kansai Center, Osaka University, the Osaka University Hospital are all acting as core research organizations of Northern Osaka Biomedical Cluster.


About the Munich Biotech Cluster m4
The State of Bavaria is the southernmost part of Germany with its capital Munich. The Greater Munich Area unites over 20,000 persons employed by more than 350 companies in the life science sector (Biotech, Pharma, CRO, suppliers and others) making Munich one of the leading biotech regions in Europe.
The region is mainly characterized by biotech SMEs where the majority started as a spin-off from one of the world renowned research institutions. These include the Ludwig-Maximilians-University and the Technical University of Munich, the Helmholtz Center Munich – German Research Center for Environmental Health, and the three Max Planck Institutes of Biochemistry, Neurobiology and Psychiatry. Two incubators in close vicinity to the universities are giving about 60 innovative biotech start-ups a home and the contacts they need to foster their innovative ideas. BioM Biotech Cluster Development GmbH, coordinator of the Munich and Bavarian Biotech Cluster, is also located in one of the biotech incubators and provides coaching, training and other services, crucial for the long-term success of Munich's innovative biotech SMEs.
The Munich Biotech Cluster m4 is characterized by a strong focus on “red (biopharmaceutical) biotechnology”. Munich’s profile has further been sharpened by the program “m4- Personalized Medicine and Targeted Therapies”, a funding program by the Federal Ministry of Education and Research, which allies industry and academia in more than 30 cooperation projects.
Diese Pressemitteilung posten:

Weitere Pressemitteilungen dieses Herausgebers

Disclaimer